Volver a la clasificación

MetLife Inc (MET)

Sobrevalorada
Financial ServicesInsurance - LifeUnited States

Fundamental

46

Precio

$94.16

Capitalización Bursátil

$60.89B

Parte 1 · Cuánto vale la empresa

Resumen

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates in six segments: Group Benefits; Retirement and Income Solutions; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, paid family and medical leave, individual disability, accidental death and dismemberment, accident and health, vision, and pet insurance, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it offers fixed, indexed-linked, and variable annuities; pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity and funded reinsurance solutions; credit insurance products; accident & health products covering hospitalization, cancer, critical illness, income protection, and scheduled medical reimbursement plans; and protection against long-term health care services. The company was incorporated in 1999 and is based in New York, New York.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 19 de septiembre de 2026 with claude-haiku-4-5 — shared with all users

P/E: 10.3Score: 63Market cap: $40.05B

Prudential bids against MetLife for the same large-employer group life and disability contracts and for the same pension risk transfer and institutional retirement mandates in the United States, often splitting the biggest deals between the two.

P/E: 20.4Score: 58Market cap: $14.42B

Unum sells the same workplace benefits package — group disability, group life and voluntary coverages — to the same US employers and brokers that MetLife's Group Benefits segment serves.

P/E: 7.9Score: 89Market cap: $34.14B

The Hartford's Employee Benefits arm competes head-on with MetLife for group life, disability and absence-management programmes at US employers of every size.

P/E: 12.1Score: 61Market cap: $56.93B

Aflac competes with MetLife in the same two markets that matter most to it: voluntary supplemental benefits sold at the US workplace, and life and health policies sold to Japanese households.

P/E: 16.1Score: 62Market cap: $24.66B

Principal chases the same small and mid-sized employers for group benefits and workplace retirement plans, and competes with MetLife Investment Management for institutional asset mandates.

Lincoln National CorporationLNC

Lincoln's Group Protection unit and its individual life and annuity lines target the same US employers and retail savers that MetLife pursues.

Balance y Liquidez

Ingresos

$2.68B

Últimos 12 meses (hasta 30/6/2026)

Beneficio Neto

$3.63B

Últimos 12 meses (hasta 30/6/2026)

Flujo de Caja Libre

-

Patrimonio Neto Total

$28.40B

Pasivo Total

$716.25B

Ratio de Liquidez

0.19

Cobertura de Intereses

8.48

Deuda/EBITDA

2.43

Beneficio Por Acción

Ingresos y Beneficio Neto

Flujo de Caja Libre

Desglose de Ingresos

Estado histórico

Márgenes en el tiempo

La deuda en el tiempo

Cuánto pesa la deuda

Cuadro de crecimiento

Crecimiento — Ingresos

Estimación de Valor Justo

AseguradoraSobrevalorado

Valor Justo

$78.06

Precio Actual

$94.16

Margen de Seguridad

-20.6%

Rango de Valor Justo

$56.93 - $99.20

Dispersión entre los métodos de valoración utilizados, no un intervalo de confianza calibrado estadísticamente.

Métodos de Estimación

Precio objetivo de los analistas:$105.75
Flujo de caja descontado (DCF):No aplicable a este tipo de empresa
Múltiplo sobre beneficios (P/E):$46.32
Fórmula de crecimiento de Graham:No aplicable a este tipo de empresa
Valor de la capacidad de generar beneficios (EPV):No aplicable a este tipo de empresa
P/B justificado:$79.02
Descuento de dividendos (Gordon):$53.74
P/FFO, fondos de operaciones:No aplicable a este tipo de empresa
Beneficios de mitad de ciclo:No aplicable a este tipo de empresa
Múltiplo sobre ingresos:No aplicable a este tipo de empresa
Consenso de Analistas:Comprar (17B / 7H / 0S)
Última Sorpresa de Resultados:+4.93%

Métricas de Valoración

Ratio P/E

18.00

ROE

11.9%

Ratio P/B

2.18

P/FCF

-

Margen Bruto

-

ROIC

-

Radar de Rentabilidad

Creación de Valor (Ventaja Competitiva)

ROIC

-

WACC

7.9%

ROIC − WACC

-

Criterios de Análisis Fundamental

Superado (11)

  • Price CAGR 7.30%
  • P/B Ratio 2.18
  • Operating Margin 245.0%
  • Interest Coverage
  • Debt/EBITDA
  • Low reliance on intangibles
  • ROE 12.9%
  • Analyst Consensus 71% Buy
  • Earnings Surprise avg 5.2%
  • Earnings Quality (OCF/NI) 4.29
  • Share Dilution -3.7%

Fallido (9)

  • EPS shows upward trend
  • EPS CAGR -0.84%
  • Debt/Equity ratio
  • Return on Tangible Assets
  • Price below Graham Number
  • DCF valuation (Unknown)
  • Revenue Growth 5Y 2.6%
  • Net Margin Trend 135.3% vs 184.4%
  • Piotroski F-Score 4/9

No disponible (8)

  • ROIC NaN%
  • Gross Margin NaN%
  • P/FCF NaN
  • Dividend Payout NaN%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

4/9

Señales mixtas: algunas áreas requieren atención

score
criteria

Calidad de los Beneficios

4.29

Alta calidad: beneficios respaldados por efectivo

Dilución de Acciones

-3.7%

Recomprando acciones. Favorable para el accionista

Participaciones institucionales

Gobernanza

Equipo Directivo

NombreCargoEdad
Mr. Michel Abbas KhalafCEO, President & Director-
Mr. Bill PappasExecutive VP and Head of Global Technology & Operations55
Ms. Marlene Beverly DebelExecutive VP, Chief Risk Officer & Head of Insurance Investments58
Mr. Ramy TadrosRegional President of U.S. Business & Head of MetLife Holdings49
Mr. John Arthur HallSenior VP, Head of Investor Relations & Executive VP and Treasurer-
Ms. Monica M. CurtisExecutive VP, Chief Legal Officer & Head of Government Relations42
Ms. Jane SlusarkChief Communications Officer-
Mr. Michael RobertsExecutive VP & Chief Marketing Officer-
Ms. Shurawl SibbliesExecutive VP & Chief Human Resources Officer53
Mr. Randy StramSenior Vice President of Group Benefits-

Riesgo de Auditoría

4

Riesgo del Consejo

3

Riesgo de Compensación

1

Riesgo de Derechos del Accionista

9

Parte 2 · El precio y el momento de entrar

Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.

Documentos

  • Informe anual (10-K)

    Un resumen anual del negocio, los resultados financieros y los riesgos de la empresa.

    Presentado el 2026-02-19

    Ver documento
  • Informe trimestral (10-Q)

    Una actualización del desempeño financiero de los últimos tres meses.

    Presentado el 2026-08-06

    Ver documento
  • Informe de hecho relevante (8-K)

    Un aviso sobre un hecho relevante, como un cambio de dirección o un anuncio importante.

    Presentado el 2026-09-24

    Ver documento

via SEC EDGAR

Historial de Resultados

via SEC EDGAR

Latest News

Recent headlines for MET, sourced from Markets Gazette.

  • 8/5/2026POSITIVE
    MetLife’s Earnings Beat Wall Street Expectations

    MetLife Inc. reported second-quarter earnings that exceeded Wall Street's projections, driven by robust underwriting performance and significant volume growth. The company's success is attributed in part to its strategic five-year plan, initiated in late 2024, which appears to be yielding positive results. This earnings beat suggests effective operational management and strategic execution, potentially signaling a favorable outlook for the insurance giant. Investors will be watching for continued momentum and the long-term impact of the company's strategic initiatives.

  • 5/28/2026NEUTRAL
    MetLife Clashes With Ares Over Struggling Football Investment

    MetLife Inc. is reportedly in a dispute with Ares Management regarding the restructuring of Eagle Football, a holding company with stakes in several football clubs, notably Olympique Lyonnais. The disagreement centers on the financial strategy and future direction of the football investment group. While the specific details of the clash are not fully disclosed, such disputes can introduce uncertainty for investors in the involved entities. The outcome could impact the valuation and operational stability of the football assets.

  • 5/6/2026POSITIVE
    MetLife’s Improved PE Returns Lift Earnings Above Expectations

    MetLife Inc. reported first-quarter earnings that exceeded Wall Street consensus, primarily driven by enhanced returns from its private equity investments. The insurer's ability to leverage its private equity portfolio for higher gains signals effective asset management and a robust strategy in alternative investments. This performance suggests a positive outlook for MetLife's financial health and could be interpreted by investors as a sign of strong operational execution and potential for future growth, especially in its alternative asset classes.

  • 2/24/2026NEUTRAL
    Polymarket users favor Meteora in bets over ZachXBT crypto takedown

    Polymarket users have wagered over $7 million on the outcome of the investigation by prominent crypto sleuth ZachXBT, with an announcement expected on Thursday. The betting patterns indicate a preference for Meteora, suggesting many investors believe the DeFi protocol will navigate the inquiry without severe repercussions. This speculative activity underscores the high tension and uncertainty surrounding crypto projects under scrutiny, as the market attempts to anticipate the impact of potential 'takedowns'. The impending announcement will be crucial in determining the future direction of the MET token, introducing potential volatility.

via Markets Gazette